FAIRE UN DON →

Essai clinique NCT03600701 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma

Couverture éditoriale Strongers pour l’étude clinique NCT03600701 (Phase II), statut : actif, non en recrutement — Recurrent Lung Non-Small Cell Carcinoma.
Recherche en oncologie 16/11/2026

NCT03600701 — est «actif (non en recrutement)» sur ClinicalTrials.gov.

Essai clinique NCT03600701 (phase II) est «actif (non en recrutement)» sur ClinicalTrials.gov.

Pathologie: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma · Interventions enregistrées: Atezolizumab, Cobimetinib · Dates enregistrées (source): 2018-11-29, 2025-07-14, 2018-07-26, 2026-11-13.

Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving atezolizumab and cobimetinib may work better in treating patients with non-small cell lung cancer.

Source: https://clinicaltrials.gov/study/NCT03600701

Une newsletter pour ceux qui concourent, qui donnent, qui croient à la recherche

Événements, bourses attribuées, histoires de celles et ceux qui rendent la recherche possible. Un email par mois, jamais de spam.